ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire  ¹     Peter L Lakatos  ²     Timothy Ritter  ³     Stephen B Hanauer  ⁴     Brian Bressler  ⁵     Reena Khanna  ⁶     Kim Isaacs  ⁷     Saumin Shah  ⁸     Alysha Khavarian Kadva  ⁹     Helen Tyrrell  ¹⁰     Young Oh  ¹⁰     Swati Tole  ¹⁰     Akiko Chai  ¹⁰     Jennifer Pulley  ¹⁰     Wenhui Zhang  ¹⁰     Brian G. Feagan  ^10    
1 University Hospital Leuven, Leuven, Belgium
² McGill University, Montreal, Canada
³ GI Alliance, Southlake, United States
⁴ Northwestern University, Chicago, United States
⁵ St. Paul’s Hospital, Vancouver, Canada
⁶ Western University, London, Canada
⁷ University of North Carolina School of Medicine, Chapel Hill, United States
⁸ Gujarat Hospital, Gastro & Vascular Center, Gujarat, India
⁹ Genentech, Inc, South San Francisco, United States
¹⁰ Roche Products Limited, Welwyn Garden City, United Kingdom

Topic
IBD

Session
Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)